NVS

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change +0.82
Percentage change 0.73	%

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN REGN VRTX

| Held by: DFIV DFIC DFAI DFAX GCOW FVD DIHP PPH AVDE PID

Scroll to Statements

Index	-	P/E	19.32	EPS (ttm)	5.87	Insider Own	0.00%	Shs Outstand	1.98B	Perf Week	1.83%
Market Cap	215.28B	Forward P/E	12.85	EPS next Y	8.83	Insider Trans	-	Shs Float	1.90B	Perf Month	0.78%
Income	11.94B	PEG	2.95	EPS next Q	2.25	Inst Own	6.90%	Short Float	0.24%	Perf Quarter	11.40%
Sales	50.32B	P/S	4.28	EPS this Y	8.35%	Inst Trans	7.64%	Short Ratio	1.82	Perf Half Y	0.28%
Book/sh	22.30	P/B	5.09	EPS next Y	4.35%	ROA	11.34%	Short Interest	4.51M	Perf Year	14.53%
Cash/sh	7.09	P/C	16.00	EPS next 5Y	6.54%	ROE	26.33%	52W Range	96.06 - 120.92	Perf YTD	16.59%
Dividend Est.	3.92 (3.46%)	P/FCF	13.25	EPS past 5Y	13.99%	ROI	17.83%	52W High	-6.18%	Beta	0.59
Dividend TTM	3.99 (3.52%)	Quick Ratio	0.84	Sales past 5Y	1.74%	Gross Margin	74.07%	52W Low	18.10%	ATR (14)	2.33
Dividend Ex-Date	Mar 12, 2025	Current Ratio	1.04	EPS Y/Y TTM	-17.73%	Oper. Margin	30.62%	RSI (14)	60.69	Volatility	1.18% 2.29%
Employees	75883	Debt/Eq	0.71	Sales Y/Y TTM	1.08%	Profit Margin	23.73%	Recom	3.04	Target Price	121.91
Option/Short	Yes / Yes	LT Debt/Eq	0.52	EPS Q/Q	-65.76%	Payout	55.39%	Rel Volume	1.02	Prev Close	112.63
Sales Surprise	1.15%	EPS Surprise	7.86%	Sales Q/Q	15.14%	Earnings	Apr 29 BMO	Avg Volume	2.48M	Price	113.45
SMA20	4.11%	SMA50	3.16%	SMA200	4.13%	Trades		Volume	2,543,503	Change	0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-13-25	Downgrade	UBS	Buy → Neutral
Feb-12-25	Initiated	Morgan Stanley	Underweight
Feb-04-25	Upgrade	Deutsche Bank	Hold → Buy
Dec-04-24	Downgrade	HSBC Securities	Hold → Reduce
Sep-11-24	Downgrade	BofA Securities	Buy → Neutral	$135 → $130
Sep-05-24	Downgrade	Goldman	Buy → Neutral
Sep-03-24	Downgrade	Jefferies	Buy → Hold
Jul-19-24	Downgrade	Deutsche Bank	Buy → Hold
May-30-24	Initiated	Goldman	Buy	$120
Feb-23-24	Initiated	BMO Capital Markets	Market Perform	$114
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$114
Jan-16-24	Resumed	UBS	Buy
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Sep-25-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-26-23	Upgrade	Deutsche Bank	Hold → Buy
Mar-27-23	Upgrade	Deutsche Bank	Sell → Hold
Jan-26-23	Downgrade	Citigroup	Buy → Neutral
Dec-05-22	Upgrade	Stifel	Hold → Buy
Sep-15-22	Downgrade	Credit Suisse	Neutral → Underperform

Show Previous Ratings

Today 03:06AM	Novartis AG (NVS) Q1 2025 Earnings Call Highlights: Impressive Growth and Strategic Advancements (GuruFocus.com)
Apr-29-25 06:25PM	Analyst Report: Novartis AG (Morningstar Research)
04:14PM	Novartis Scores A Beat-And-Raise Quarter And Shares Make A Break For A Buy Point (Investor's Business Daily)
03:00PM	Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry (CNBC TV)
02:09PM	Novartis AG (NVS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
01:00PM	Loading…
01:00PM	Novartis CEO on earnings: Launch drivers like breast cancer, MS medicines are performing really well (CNBC TV)
11:04AM	INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:30AM	Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics (Zacks)
09:28AM	Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up (Zacks)
09:25AM	Novartis Creeps Toward A Breakout On Its Beat-And-Raise (Investor's Business Daily)
05:04AM	Novartis: Q1 Earnings Snapshot (Associated Press Finance)
03:15AM	Novartis Lifts Guidance After Profit, Sales Top Views (The Wall Street Journal)
01:00AM	Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1 (GlobeNewswire)
Apr-28-25 11:25PM	Franklin Mutual Shares Fund Q1 2025 Commentary (Seeking Alpha)
08:45AM	Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access (Reuters)
07:28AM	Loading…
07:28AM	3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. (MarketBeat)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-26-25 10:15AM	These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys? (Motley Fool)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
Apr-23-25 01:52PM	Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle (Seeking Alpha)
09:50AM	Why Novartis (NVS) is a Top Momentum Stock for the Long-Term (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
04:40AM	Oakmark Global All Cap Strategy Q1 2025 Commentary (Seeking Alpha)
02:44AM	European pharma companies push for higher drug prices in EU amid U.S. tariff threats (Reuters)
Apr-22-25 08:35AM	Swiss Pharma Giant Roche To Invest $50B in US Amid Tariff Threat (Investopedia)
Apr-21-25 01:36PM	Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? (Zacks)
08:00AM	3 Momentum Stocks That Could Soar Post-Market Volatility (MarketBeat)
07:30AM	uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold (Seeking Alpha)
11:45AM	Loading…
Apr-18-25 11:45AM	Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio (Zacks)
Apr-17-25 08:56AM	2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever (Motley Fool)
08:50AM	Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
04:00AM	Novartis scores NFL deal to tackle health outcomes (Pharma Voice)
Apr-16-25 11:32AM	TG Therapeutics: Progress In MS Tempered By High Expectations (Seeking Alpha)
09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
08:54AM	Dodge & Cox International Stock Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-15-25 08:08AM	Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke (TipRanks)
Apr-14-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
02:30AM	Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains? (Zacks)
02:17AM	The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis (Zacks)
Apr-11-25 05:01PM	Novartis Commits $23 Billion to U.S. Expansion, Eyes Full Domestic Production of Key Medicines (GuruFocus.com)
01:17PM	NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat (Zacks)
12:55PM	Novartis commits $23bn to US manufacturing amid tariff threats (Pharmaceutical Technology)
11:47AM	Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More (Zacks)
09:32AM	Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing (The Wall Street Journal)
08:28AM	This Pharma Giant Will Invest $23 Billion in the U.S. Its a Sign Trumps Tariffs Are Working. (Barrons.com)
07:53AM	Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Novartis (The Wall Street Journal)
Apr-10-25 05:52PM	Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs (Investopedia)
05:08PM	Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats (The Wall Street Journal)
04:51PM	Novartis to spend $23B to expand in the US (Yahoo Finance Video)
01:57PM	Amid tariff turmoil, Novartis commits to spending $23B on U.S. manufacturing (BioPharma Dive)
01:33PM	Novartis plans to invest $23 billion in US sites as Trump renews drug tariff threats (Reuters)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
08:17AM	Novo Nordisk, AbbVie, Other Stocks Tumble After Trump Threatens Pharma Tariffs (The Wall Street Journal)
06:17AM	Pharma Stocks Drop After Trump Threatens Tariffs on Medicines (The Wall Street Journal)
05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire)
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-07-25 01:00AM	This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. (Barrons.com)
Apr-06-25 06:38AM	Novartis After Sandoz: The Business Without Generics (Seeking Alpha)
Apr-04-25 09:46AM	Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure (Zacks) -5.71%
07:22AM	Trial monitors recommend Elevidys studies continue; Novartis kidney drug approved (BioPharma Dive)
Apr-03-25 12:10PM	Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year (Benzinga)
10:46AM	FDA Grants Accelerated Approval to NVS Kidney Disease Drug (Zacks)
Apr-02-25 08:29PM	Novartis receives FDA accelerated approval for Vanrafia (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN) (PR Newswire)
06:03PM	Big Pharma Avoids Worst-Case Tariff Scenario (The Wall Street Journal)
11:45AM	Novartis (NVS) Could Be a Great Choice (Zacks)
09:11AM	APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag (Zacks)
08:20AM	Leqembis EU review drags on; Sanofi gets a new development head (BioPharma Dive)
Mar-31-25 03:03PM	Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (Seeking Alpha)
09:43AM	Isomorphic raises $600M on big ambitions for AI drugmaking tech (BioPharma Dive)
09:40AM	JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer (Zacks)
01:00AM	Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis (GlobeNewswire)
Mar-30-25 05:00AM	Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors (Seeking Alpha)
Mar-28-25 01:18PM	FDA broadens use of Novartis radiopharma drug Pluvicto (BioPharma Dive)
12:52PM	FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer (GlobeNewswire)
09:44AM	AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (Seeking Alpha)
09:40AM	Here's Why Novartis (NVS) is a Strong Value Stock (Zacks)
Mar-27-25 04:55PM	Analyst Report: Novartis AG (Morningstar Research)
08:30AM	Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-25-25 06:47AM	5 Large Drug Stocks to Watch as Industry Recovers (Zacks)
02:15AM	Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis (GlobeNewswire)
Mar-24-25 11:06PM	Wasatch Global Value Fund Q4 2024 Commentary (SeekingAlpha)
02:59PM	Tempero secures $70m to advance addiction treatment candidate (Pharmaceutical Technology)
08:50AM	Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names (Zacks)
08:45AM	Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains (Zacks)
Mar-23-25 12:00PM	Lantheus Holdings: One Blockbuster, Evolving Pipeline (SeekingAlpha)
Mar-22-25 11:41AM	Morgan Stanley says Fabhaltas label leaves opportunity for Apellis Empaveli (TipRanks)
Mar-21-25 02:10PM	FDA Approves Novartis Drug for Rare Kidney Disease Treatment (Zacks)
12:46PM	Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy (Zacks)
12:26PM	Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals (Zacks)
11:36AM	FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease (Benzinga)
08:15AM	AstraZeneca deepens China investment; Editas loses CFO to Dyne (BioPharma Dive)
07:42AM	FDA approves Novartis' Fabhalta for C3 glomerulopathy treatment (Pharmaceutical Business Review)
07:21AM	Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (SeekingAlpha)
02:21AM	Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G (SeekingAlpha)
Mar-20-25 07:37PM	Novartis receives third FDA approval for oral Fabhalta (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) (PR Newswire)
12:42PM	Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 (SeekingAlpha)

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kowalski Robert William	Officer	Aug 12 '24	Proposed Sale	111.72	6,566	733,572		Aug 12 03:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Novartis AG ADR

Upgrade your FINVIZ experience